Oryzon Genomics S.A
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, … Read more
Oryzon Genomics S.A (ORYZF) - Net Assets
Latest net assets as of September 2025: $136.97 Million USD
Based on the latest financial reports, Oryzon Genomics S.A (ORYZF) has net assets worth $136.97 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($171.04 Million) and total liabilities ($34.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $136.97 Million |
| % of Total Assets | 80.08% |
| Annual Growth Rate | 17.53% |
| 5-Year Change | 14.63% |
| 10-Year Change | 215.45% |
| Growth Volatility | 31.42 |
Oryzon Genomics S.A - Net Assets Trend (2013–2024)
This chart illustrates how Oryzon Genomics S.A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oryzon Genomics S.A (2013–2024)
The table below shows the annual net assets of Oryzon Genomics S.A from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $87.04 Million | +6.44% |
| 2023-12-31 | $81.77 Million | +12.68% |
| 2022-12-31 | $72.57 Million | +1.84% |
| 2021-12-31 | $71.26 Million | -6.15% |
| 2020-12-31 | $75.93 Million | +24.21% |
| 2019-12-31 | $61.13 Million | +35.47% |
| 2018-12-31 | $45.13 Million | +31.06% |
| 2017-12-31 | $34.43 Million | +51.49% |
| 2016-12-31 | $22.73 Million | -17.63% |
| 2015-12-31 | $27.59 Million | +98.61% |
| 2014-12-31 | $13.89 Million | -5.67% |
| 2013-12-31 | $14.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oryzon Genomics S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1512725300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.29 Million | 3.78% |
| Other Components | $103.09 Million | 118.44% |
| Total Equity | $87.04 Million | 100.00% |
Oryzon Genomics S.A Competitors by Market Cap
The table below lists competitors of Oryzon Genomics S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NITTETSU MNG CO.LTD
F:7GI
|
$187.55 Million |
|
Trifork Holding AG
CO:TRIFOR
|
$187.71 Million |
|
Wereldhave Belgium Naamloze vennootschap
F:WPU
|
$187.82 Million |
|
Wuhan Citms Technology Co Ltd
SHG:688038
|
$187.85 Million |
|
Jiujiang Shanshui Technology Co.Ltd
SHE:301190
|
$187.44 Million |
|
Weyco Group Inc
NASDAQ:WEYS
|
$187.41 Million |
|
Long Chen Paper Co Ltd
TW:1909
|
$187.28 Million |
|
Rain Industries Limited
NSE:RAIN
|
$187.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oryzon Genomics S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 81,774,637 to 87,042,434, a change of 5,267,797 (6.4%).
- Net loss of 3,665,417 reduced equity.
- Other comprehensive income decreased equity by 2,505,621.
- Other factors increased equity by 11,438,835.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.67 Million | -4.21% |
| Other Comprehensive Income | $-2.51 Million | -2.88% |
| Other Changes | $11.44 Million | +13.14% |
| Total Change | $- | 6.44% |
Book Value vs Market Value Analysis
This analysis compares Oryzon Genomics S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.31x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.88x to 2.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.63 | $3.10 | x |
| 2014-12-31 | $0.49 | $3.10 | x |
| 2015-12-31 | $1.00 | $3.10 | x |
| 2016-12-31 | $0.82 | $3.10 | x |
| 2017-12-31 | $1.03 | $3.10 | x |
| 2018-12-31 | $1.17 | $3.10 | x |
| 2019-12-31 | $1.16 | $3.10 | x |
| 2020-12-31 | $1.44 | $3.10 | x |
| 2021-12-31 | $1.35 | $3.10 | x |
| 2022-12-31 | $1.29 | $3.10 | x |
| 2023-12-31 | $1.34 | $3.10 | x |
| 2024-12-31 | $1.34 | $3.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oryzon Genomics S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -49.81%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.25x
- Recent ROE (-4.21%) is below the historical average (-3.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -14.66% | -91.45% | 0.08x | 1.95x | $-3.63 Million |
| 2014 | 47.87% | 42.81% | 0.60x | 1.88x | $5.26 Million |
| 2015 | -3.59% | -13.81% | 0.18x | 1.48x | $-3.75 Million |
| 2016 | -23.97% | -108.76% | 0.10x | 2.19x | $-7.72 Million |
| 2017 | -15.09% | -120.38% | 0.07x | 1.77x | $-8.64 Million |
| 2018 | -2.61% | -17.36% | 0.10x | 1.49x | $-5.69 Million |
| 2019 | -6.03% | -35.85% | 0.13x | 1.31x | $-9.80 Million |
| 2020 | -4.48% | -35.71% | 0.10x | 1.24x | $-10.99 Million |
| 2021 | -6.58% | -44.15% | 0.11x | 1.34x | $-11.81 Million |
| 2022 | -5.83% | -26.95% | 0.15x | 1.43x | $-11.49 Million |
| 2023 | -4.10% | -23.63% | 0.13x | 1.31x | $-11.53 Million |
| 2024 | -4.21% | -49.81% | 0.07x | 1.25x | $-12.37 Million |
Industry Comparison
This section compares Oryzon Genomics S.A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oryzon Genomics S.A (ORYZF) | $136.97 Million | -14.66% | 0.25x | $187.46 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |